Clinical Trial Update: Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients. [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing a FeNO cut-off to predict response to budesonide-formoterol in patients with cough-variant asthma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough-variant Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Cough-Variant Asthma | Phase 4 | Status: COMPLETED